Global Rheumatoid Arthritis Drugs Market 2018-2022 - Product Image

Global Rheumatoid Arthritis Drugs Market 2018-2022

  • ID: 4703277
  • Report
  • Region: Global
  • 111 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB Pharma
  • MORE
The use of biologics and biosimilars for the treatment of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA. Analysts have predicted that the rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.

Market Overview

Increasing need for affordable biologics for rheumatoid arthritis

Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.

Low access to healthcare due to social stigma

Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.

For the detailed list of factors that will drive and challenge the growth of the rheumatoid arthritis drugs market during the 2018-2022, view the report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Amgen and Novartis the competitive environment is quite intense. Factors such as the use of biologics and biosimilars for the treatment of RA and increasing need for affordable biologics for rheumatoid arthritis, will provide considerable growth opportunities to rheumatoid arthritis drugs manufactures. AbbVie, Amgen, Novartis, Pfizer, UCB Pharma, and Johnson & Johnson are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. Many established rheumatoid arthritis drug companies are vying for their share of the global rheumatoid arthritis drugs market, and players must differentiate themselves to gain vital traction over their competitors.’
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB Pharma
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULE
  • Segmentation by type of molecule
  • Comparison by type of molecule
  • Biologics - Market size and forecast 2017-2022
  • Small molecules - Market size and forecast 2017-2022
  • Market opportunity by type of molecule
PART 09: MARKET SEGMENTATION BY TYPE OF RA
  • Segmentation by type of RA
  • Seropositive RA
  • Seronegative RA
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • High cost of RA drugs
  • Use of biologics/biosimilars for treatment of RA
  • Use of gene therapy for RA treatment
  • Market dominance by TNF-alpha inhibitors
  • Need for rheumatologists
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB Pharma
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global immunology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for RA
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Type of molecule - Market share 2017-2022 (%)
Exhibit 20: Comparison by type of molecule
Exhibit 21: Biologics - Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Biologics - Year-over-year growth 2018-2022 (%)
Exhibit 23: Small molecules - Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Small molecule - Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by type of molecule
Exhibit 26: Customer landscape
Exhibit 27: Global - Market share by geography 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 33: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: AbbVie - Overview
Exhibit 45: AbbVie - Business segments
Exhibit 46: AbbVie - Organizational developments
Exhibit 47: AbbVie - Geographic focus
Exhibit 48: AbbVie - Segment focus
Exhibit 49: AbbVie - Key offerings
Exhibit 50: Amgen - Overview
Exhibit 51: Amgen - Business segments
Exhibit 52: Amgen - Organizational developments
Exhibit 53: Amgen - Geographic focus
Exhibit 54: Amgen - Segment focus
Exhibit 55: Amgen - Key offerings
Exhibit 56: Johnson & Johnson - Overview
Exhibit 57: Johnson & Johnson - Business segments
Exhibit 58: Johnson & Johnson - Organizational developments
Exhibit 59: Johnson & Johnson - Geographic focus
Exhibit 60: Johnson & Johnson - Segment focus
Exhibit 61: Johnson & Johnson - Key offerings
Exhibit 62: Novartis - Overview
Exhibit 63: Novartis - Business segments
Exhibit 64: Novartis - Organizational developments
Exhibit 65: Novartis - Geographic focus
Exhibit 66: Novartis - Segment focus
Exhibit 67: Novartis - Key offerings
Exhibit 68: Pfizer - Overview
Exhibit 69: Pfizer - Business segments
Exhibit 70: Pfizer - Organizational developments
Exhibit 71: Pfizer - Geographic focus
Exhibit 72: Pfizer - Segment focus
Exhibit 73: Pfizer - Key offerings
Exhibit 74: UCB Pharma - Overview
Exhibit 75: UCB Pharma - Business segments
Exhibit 76: UCB Pharma - Organizational developments
Exhibit 77: UCB Pharma - Geographic focus
Exhibit 78: UCB Pharma - Segment focus
Exhibit 79: UCB Pharma - Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB Pharma
  • MORE
The author of the report recognizes the following companies as the key players in the global rheumatoid arthritis drugs market: AbbVie, Amgen, Novartis, Pfizer, UCB Pharma, and Johnson & Johnson.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the use of biologics and biosimilars for the treatment of RA.”

According to the report, one of the major drivers for this market is the increasing need for affordable biologics for rheumatoid arthritis.

Further, the report states that one of the major factors hindering the growth of this market is the low access to healthcare due to social stigma.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB Pharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll